Tuesday, July 23, 2024

Warning: Undefined variable $getmfsource in /home/thescizo/www/www/wp-content/themes/Newspaper-SCI-Zone/functions.php on line 224
HomeAnswersWhat is NIL-A?

What is NIL-A?

NIL-A is a neuroimmunophilin that was developed by Guilford and Amgen for Parkinson’s disease [1]. A second generation product, NIL-A succeeds an earlier immunophilin product called GPI-1046. Preclinical development of GPI-1046 itself appears to have been suspended [2]. Data from efficacy and pharmacokinetic studies with NIL-A were presented at the Acute Neuronal Injury: New Therapeutic Opportunities meeting in August of 1998, Las Vegas, USA. The compound apparently possesses 50% oral bioavailability, and approximately 25 fold greater efficacy compared with GPI 1046, as well as a superior half life and absorption profile.

The investment community has been enthusiastic about NIL-A, suggesting that the drug may be a potential blockbuster with the potnetial for $1 billion in annual sales [3]. Details concerning the structure of NIL-A is not yet available. According to www.biospace.com [4], NIL-A is a modified form of GPI-1046 that is more potent, is longer lasting, and can be taken orally. In the meanwhile serious questions have been raised concerning the efficacy of GPI-1046

This site uses Akismet to reduce spam. Learn how your comment data is processed.

- Advertisment -

Must Read

Study identifies drug target to prevent autonomic dysfunction after spinal cord...

In response to stressful or dangerous stimuli, nerve cells in the spinal cord activate involuntary, autonomic reflexes often referred to as "fight or flight"...